Showing results (111-120 of 157) with videos related to
Sort By:
Pageof 16
Molecular Oncology|January 31, 2014
Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanomaMatteo S Carlino, Jason R Todd, Kavitha Gowrishankar, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 4, 2014
Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatmentJames S Wilmott, Lauren E Haydu, Alexander M Menzies, et al.The Journal of Investigative Dermatology|August 8, 2013
Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stressAmanda Croft, Kwang H Tay, Suzanah C Boyd, et al.Cancer Immunology, Immunotherapy : CII|January 1, 2018
Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case reportHelen M McGuire, Elena Shklovskaya, Jarem Edwards, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2006
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study GroupAgop Y Bedikian, Michael Millward, Hubert Pehamberger, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2002
Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trialPeter Hersey, Alan S Coates, William H McCarthy, et al.Histopathology|June 28, 2012
Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasisRamin Shayan, Tara Karnezis, Rajmohan Murali, et al.Pigment Cell & Melanoma Research|June 14, 2014
Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151Stuart J Gallagher, Branka Mijatov, Dilini Gunatilake, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma PatientsHojabr Kakavand, James S Wilmott, Alexander M Menzies, et al.American Journal of Therapeutics|June 11, 2014
Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countriesAlberto Wainstein, Salvador Martin Algarra, Lars Bastholt, et al.Pageof 16